Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
4.7%
0.90
1.30
0.28
1.37%
-9.6%
88.95
Nifty 100 benchmark
17.1%
0.23
0.32
—
—
-37.0%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
82 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
432
-1.7%
8.8%
23.8%
1%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
InvestVerdict
Edelweiss Equity Savings Fund
Regular Plan · Growth
Allocation
By asset
Equity
72.03%
Debt
10.09%
Unclassified
8.92%
REITs / InvITs
1.27%
Foreign Securities
0.02%
By market cap
Large Cap
44.54%
Mid Cap
15.08%
Small Cap
9.28%
Unclassified
23.43%
Concentration
Number of stocks
147
Top 5 stocks
21.22%
Top 10 stocks
37.36%
Top 20 stocks
53.92%
Largest holding
5.87%
Largest sector
Banks 15.34%
Effective stocks
50.9
Cash
-32.41%
InvestVerdict
Edelweiss Equity Savings Fund
Regular Plan · Growth · holdings
Top 18 holdings
#
Company
Sector
% of fund
1
—
Banks
5.87%
2
—
Unclassified
5.38%
3
—
Banks
4.28%
4
—
Telecom - Services
3.74%
5
—
Power
3.72%
6
—
Unclassified
3.61%
7
—
Ferrous Metals
3.61%
8
—
CRISIL AAA
3.46%
9
—
Petroleum Products
3.32%
10
—
Telecom - Services
3.18%
11
—
Unclassified
2.57%
12
—
Unclassified
2.56%
13
—
Realty
2.04%
14
—
Unclassified
1.89%
15
—
SOVEREIGN
1.78%
16
—
CRISIL AAA
1.72%
17
—
CRISIL AAA
1.72%
18
—
Fertilizers & Agrochemicals
1.58%
Sector split
Unclassified
8.92%
Cash & Equivalents
7.65%
CRISIL AAA
7.60%
Banks
4.30%
Realty
3.02%
SOVEREIGN
2.49%
Capital Markets
2.44%
Finance
2.23%
Pharmaceuticals & Biotechnology
1.92%
Power
1.72%
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹769,073
₹169,073
9.88%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 29 Aug 2026.